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A Previously Unknown Dermal Blood Vessel
Phenotype in Skin Inflammation
Marion Gro¨ger1, Heide Niederleithner1, Dontscho Kerjaschki2 and Peter Petzelbauer1
Podoplanin and lymphatic vascular endothelial hyaluronan receptor-1 (LYVE-1) are considered as lineage
markers for lymphatic vessel (LV) endothelial cells (LECs). We have recently shown that IL-3 induces de novo
expression of these genes in cultured blood vessel (BV) endothelial cells (BEC). To ask, if this is trans-
differentiation or activation, we analyzed inflamed skin samples and cytokine-stimulated organ-cultured skin
and found a subset of blood capillaries within the papillary dermis expressing low amounts of podoplanin and
LYVE-1 as well as high amounts of cytokine-inducible adhesion molecules. In contrast, neighboring lymphatic
capillaries express high amounts of podoplanin, LYVE-1 and low amounts of cytokine-inducible adhesion
molecules. The different response patterns to inflammatory stimuli were reproducible in cell culture, when
cytokine-stimulated BEC and LEC were analyzed. These findings signify that expression of ‘‘lymphatic proteins’’
on BEC corresponds to cell activation.
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INTRODUCTION
Blood endothelial cells (BEC) and lymphatic endothelial cells
(LEC) differ by morphology and protein expression patterns.
Blood capillaries are best characterized by the continuous
basement membrane investing the lumen and by a surround-
ing layer of smooth muscle actin (SMA)-positive smooth
muscle cells and pericytes (Braverman, 2000; Helmbold
et al., 2001). In contrast, lymphatic capillaries possess a
discontinuous basement membrane and no surrounding
smooth muscle cells or pericytes (Sauter et al., 1998).
At the protein level, a growing number of discriminative
marker proteins have been identified. Among others, BEC
express endothelial antigen PAL-E (Schlingemann et al.,
1985), N-cadherin (Petrova et al., 2002; Podgrabinska
et al., 2002; Hirakawa et al., 2003), and CXCR-4 (Petrova
et al., 2002; Podgrabinska et al., 2002). LEC express
prospero-related homeobox 1 (Prox-1) (Wigle et al., 2002),
podoplanin (Breiteneder-Geleff et al., 1999; Kriehuber et al.,
2001), VEGFR-3 (Kaipainen et al., 1995; Karkkainen et al.,
2002), D6 (Nibbs et al., 2001), and lymphatic vascular
endothelial hyaluronan receptor-1 (LYVE-1) (Banerji et al.,
1999). In normal tissues, immunostainings with the respective
antibodies (Abs) results in a virtually exclusive reactivity with
blood or lymphatic vessels (LVs) (Kriehuber et al., 2001;
Petrova et al., 2002; Hirakawa et al., 2003).
In contrast to the lineage-specific expression profile of
unstimulated cells, stimulation with IL-3 (Gro¨ger et al., 2004),
IL-7 (Al-Rawi et al., 2005), HHV8 infection (Carroll et al.,
2004; Hong et al., 2004; Wang et al., 2004), or over-
expression of Prox-1 (Hong et al., 2002; Petrova et al., 2002),
has been shown to induce expression of podoplanin and
LYVE-1 in cultured BEC. We therefore aimed to investigate,
whether true blood capillaries in vivo may express lymphatic
markers. Results were compared with cytokine-stimulated
organ-cultured skin samples and cytokine-stimulated cultures
of BEC and LEC. Here, we describe a previously unknown
‘‘inflammatory’’ phenotype of BEC, expressing low amounts
of podoplanin and LYVE-1 and high amounts of E-selectin,
ICAM-1, and VCAM-1.
RESULTS
Podoplanin and LYVE-1 are expressed on blood capillaries of
inflamed skin
Skin sections of formalin-fixed and paraffin-embedded
biopsies were taken from normal skin, eczema, and psoriasis
and analyzed for podoplanin expression. In normal skin—as
expected—we found two types of vessels, the first expressing
high levels of podoplanin representing LVs and the other
being negative for podoplanin representing blood vessels
(BVs, Figure 1a). In contrast, within the papillary dermis from
eczema and psoriasis we found a third type of vessel
expressing low amounts of podoplanin (Figure 1b–d). Some
of them contained red blood cells within their lumina,
suggesting that they belong to the BV tree (Figure 1b and c).
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Moreover, in psoriatic skin, the tortuous vessels within the
tips of the papillae also displayed this podoplaninlowþ
phenotype (Figure 1d). Both, the mAb and the polyclonal
anti-podoplanin Abs gave identical staining patterns (Figure
1c and d). Preincubation with the recombinant podoplanin
protein resulted in a complete loss of staining (Figure 1e and f).
Also the rabbit pre-immune serum gave negative results
(Figure 1h).
Similar to results seen with podoplanin, also stainings with
anti-LYVE-1 Abs revealed two types of LYVE-1þ vessels,
one expressing high and the other low amounts of LYVE-1
(Figure 1g). In the reticular dermis expression of podoplanin
or LYVE-1 was only seen in LV but not in BV (data not
shown).
The population of podoplaninlowþ vessels was further
characterized in triple stained specimen; CD31 to determine
the total number of vessels, anti-SMA stains to identify BVs,
and anti-podoplanin (Figure 2). In the papillary dermis of
normal skin, all CD31þ /SMAþ BVs were podoplanin and
all CD31þ /SMA LVs were podoplaninhighþ giving a clear
distinction between both vascular beds. In contrast to normal
skin, most BVs of eczema and psoriasis expressed low
amounts of podoplanin (examples are provided in Figure 2;
for summary see Table 1). As an additional control, urticarial
skin lesions were analyzed, which gave virtually the same
picture as normal skin (Table 1).
Podoplanin and LYVE-1 are induced on BVs in organ culture
Organ culture allows cytokine stimulation and evaluation of
protein expression of cells in situ. Moreover, by using cryostat
sections, the affiliation podoplaninlowþ or LYVE-1lowþ
vessels can be further defined by the BV marker PAL-E
(Schlingemann et al., 1985). In controls (unstimulated organ-
cultured skin), all PAL-Eþ vessels were surrounded by SMAþ
cells, confirming that BVs of the papillary dermis can be
defined by the surrounding of SMAþ cells. They were
negative for podoplanin (Figure 3) and LYVE-1 (data not
shown). All LVs were PAL-E and devoid of surrounding
SMAþ cells, and expressed podoplanin (Figure 3) and LYVE-
1 (data not shown). Isotype controls were negative (Figure 3).
Upon stimulation with IL-3 or more pronounced with a
combination of TNFa, IFNg plus IL-3, most PAL-Eþ /SMAþ
BVs were found to express podoplanin and LYVE-1. Of note,
not only BVs but also some LVs coexpressed E-selectin.
Examples are shown in Figure 3, the summary of responding
vessels is shown in Figure 4. Prox-1 was never detectable on
PAL-Eþ vessels (data not shown).
Definition of cytokine response profiles in cultured BEC and
LEC
To quantify the amount of protein expression following
cytokine stimulation, we performed FACS analysis of cultured
BEC and LEC. Following 24 hours of stimulation with TNFa,
TNFaþ IFNg, or TNFaþ IFNgþ IL-3 (Figure 5a), BEC can be
defined as podoplaninlowþ , E-selectinhighþ , ICAM-1highþ ,
VCAM-1highþ , whereas LEC were podoplaninhighþ ,
E-selectinþ /, ICAM-1lowþ , VCAM-1þ /. IL-3 induced low
amounts of podoplanin in all BEC, which differs from the in
vivo situation, where only a subset of BV expressed
podoplanin (Figure S1). IL-3 induced low amounts of
E-selectin in both BEC (Brizzi et al., 1993; Gro¨ger et al.,
2004) and LEC, IFNg super-induced TNF-induced VCAM-1
expression in BEC (Lechleitner et al., 1998), but not in LEC.
Of note, also after 6 hours of cytokine stimulation, E-selectin
expression was significantly lower in LEC compared with BEC
(comparable to 24 hours levels; not shown). Examples for
individual FACS curves for podoplanin and the adhesion
molecules following 24 hours cytokine stimulation are shown
in Figures S1 and S2; results for 72 hours of cytokine
Normal skin, podoplanin (mAb) Eczema, podoplanin (mAb)
Psoriasis, podoplanin polyclonalPsoriasis, podoplanin (mAb)
Psoriasis, LYVE-1 Isotype control
Podoplanin polyclonal Podoplanin polyclonal
+rec. podoplanin
Figure 1. Psoriasis and eczema skin samples contain a population of
podoplaninlowþ and LYVE-1lowþ vessels, some of which contain
erythrocytes, suggesting that they belong to the BV tree. Formalin-fixed,
paraffin-embedded skin samples were deparaffinized and subjected to
immunohistochemistry. BV denotes blood vessel, LV denotes LV. (a) Normal
skin sample showing a podoplanin BV and a podoplaninþ LV. (b, c) Eczema
and psoriasis: BVs containing erythrocytes within their lumina are
podoplaninlowþ . (d) Psoriasis: podoplaninlowþ vessels within the tips of the
papillae. (e, f) Serial sections of eczema, in (e) stained with the polyclonal
rabbit anti-podoplanin serum showing podoplaninþ vessels and some
podoplaninþ inflammatory cells; (f) serial section; the anti-podoplanin Ab
was preincubated with recombinant podoplanin protein, which abolished Ab
reactivity. (g) Psoriasis: BVs with erythrocytes within lumina are LYVE-1lowþ .
(h) Isotype control. Bars: a–d, g¼ 20mm; e, f, and h¼100 mm.
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stimulation are shown in Figure S3. Results obtained by FACS
were confirmed by real-time PCR, changes in cytokine-
induced mRNA expression followed results obtained by FACS
(Figure 5b and c). In summary, cytokine-induced phenotypic
changes obtained in cultured BEC and LEC mirrored
phenotypic changes seen on vessels in organ culture and in
inflamed skin.
DISCUSSION
Here, we describe a previously unknown cytokine-induced
phenotype of BEC within the papillary dermis of the skin. In
addition to their well-recognized ability to express high levels
of adhesion molecules E-selectin, ICAM-1, and VCAM-1
(Brizzi et al., 1993; Gerritsen et al., 1993; Lechleitner
et al., 1998), BEC coexpressed low levels of podoplanin
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Figure 2. Podoplaninlowþ vessels are always surrounded by SMA-positive cells, suggesting that they belong to the BV tree. Formalin-fixed, paraffin embedded
skin samples were deparaffinized and subjected to three-color immunofluorescence. CD31 in blue, SMA in red, podoplanin in green. Normal skin (first row):
a BV positive for CD31, negative for podoplanin, and surrounded by SMAþ cells. Second row: an LV positive for CD31, positive for podoplanin, and not
surrounded by SMAþ cells. Eczema skin (third row): a BV positive for CD31, low positive for podoplanin, and surrounded by SMAþcells. Fourth row: an
LV positive for CD31, positive for podoplanin, and not surrounded by SMAþ cells.
Table 1. In eczema and psoriasis skin, the majority of CD31+/SMA+ BVs express low amounts of podoplanin
Normal skin Urticaria Eczema Psoriasis
Podoplaninnegative blood vessel1 65% (+7)2 68% (+7) 8% (+8)* 9% (+11)*
Podoplaninlow+ blood vessel 0% 5% (+8) 61% (+12)* 69% (+14)*
Podoplaninhigh+ lymphatic vessel3 35% (+8) 27% (+6) 31% (+6) 22% (+8)
100%4 100% 100% 100%
BV, blood vessel; SMA, smooth muscle actin.
Numbers of vessels were quantified on triple stained laser scan images, as exemplified in Figure 2.
1CD31+/SMA+ vessels were considered as blood vessels.
2Mean7SD; n=9 in each condition, mean; *Po0.05 as compared with normal skin and urticaria.
3CD31+/SMA vessels were considered as lymphatic vessels.
4The total number of vessels was defined by CD31 reactivity and was set to 100%.
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Control
IL-3 stimulated
TNF+IFN+IL-3 stimulated
PAL-E+ SMA+
CD31+ BV
PAL-E– podoplanin+
BV
LV
PAL-E+ podoplanin+
CD31+ LV
PAL-E– podoplanin+
SMA+ BV
E-selectin+ LYVE-1+
SMA– LV
E-selectin+ LYVE-1+
SMA+ BV
E-selectin+ LYVE-1+
SMA– LV
E-selectin+ LYVE-1+
BV
PAL-E+ LYVE-1+ SMA+
LV
PAL-E– LYVE-1+ SMA–
SMA+ BV
PAL-E+ podoplanin+
Figure 3. Blood vessels of cytokine-stimulated, organ-cultured skin express podoplanin and LYVE-1. Four millimeter punch biopsies from normal were placed
in organ culture for 24 hours without (controls) or with the addition of the indicated cytokines. Thereafter, cryostat sections were subjected to three-color
immunofluorescence. The respective Ab used is indicated in each image; the images on the right side show overlays of triple stains. Dotted arrows denote LVs;
solid arrows denote BVs. (a) Controls (top row), PAL-Eþ /SMAþ BVs are podoplanin. Isotype controls were negative (lower row). (b, c) IL-3 (b) and even more
robust the combination of TNFa/IFNg/IL-3 (c) induced podoplanin, LYVE-1 and E-selectin on BVs and also E-selectin on LVs. Bar¼ 20mm.
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and LYVE-1. Clearly distinct from BEC, LEC express high
levels of podoplanin and LYVE-1, but low levels of E-selectin,
ICAM-1, and VCAM-1. The ability of LEC to express cytokine-
induced adhesion molecules in culture has been described
recently (Johnson et al., 2006), but was not compared with
BEC from the same donor. More important and in contrast to
previous studies, we have analyzed phenotypes of BEC and
LEC in situ, which allows clear assignment of EC to the
lymphatic or BV tree. We took advantage of the fact that BVs
in situ are always surrounded by a layer of smooth muscle
cells. Of note, SMAþ cells also surround collecting LVs, but
the herein described podoplaninlowþ , LYVE-1lowþ BVs were
found within the superficial vascular plexus, at sites where
these collectors are either absent or very few in number
(Braverman, 2000; Karpanen and Makinen, 2006). Moreover,
these podoplaninlowþ , LYVE-1lowþ BVs also expressed PAL-E,
an established BV marker (Schlingemann et al., 1985;
Kriehuber et al., 2001). These findings strongly favor the
concept that podoplanin and LYVE-1 expression on BEC is a
sign of cell activation and not trans-differentiation of BEC into
LEC. Of note, we were unable to induce Prox-1 on BV in situ,
which contrasts the finding that Prox-1 was inducible in our
cultured cells. The molecular basis of this phenomenon is
unclear, as it is unknown whether expression of these three
molecules is always synchronized. For example, following
HHV8 infection Carroll et al. (2004) and Hong et al. (2004)
detected expression of podoplanin, LYVE-1, and Prox-1 in
BEC, whereas Wang et al. (2004) did not see Prox-1
expression in BEC under the same conditions.
This raises the question on the function of these
‘‘lymphatic proteins’’ on BVs. In vivo, podoplaninlowþ and
LYVE-1lowþ vessels were mostly surrounded by a dense
CD45ROþ infiltrate allegorizing them as ‘‘centers of activa-
tion’’. Indirect evidence exists that both molecules are
involved in leukocyte adhesion. LYVE-1 contains a hyalur-
onan-binding domain termed ‘‘Link’’ module (Banerji et al.,
1999). Based on sequence similarities with CD44, another
hyaluronan-binding molecule, LYVE-1 could support leuko-
cyte adhesion (Jackson, 2004). With regard to podoplanin, it
induces platelet aggregation by interacting with platelet
surfaces in a sialylated O-glycan-dependent manner (Kato
et al., 2003; Kaneko et al., 2004). Sialylated O-glycans serve
pro- and antiadhesive functions and mediate leukocyte
rolling on endothelial surfaces (Fukuda, 2002). Anyway, a
direct role for podoplanin and LYVE-1 in leukocyte rolling or
adhesion to BVs has yet to remain hypothetical.
The observation that podoplaninlowþ , LYVE-1lowþ BVs
are found in chronic skin lesions like eczema or psoriasis and
not in acute urticarial rashes deserves additional comments.
Inflammatory cells in eczema or psoriasis are mainly
lymphocytes (Gaspari, 2006), whereas in urticarial rashes,
the infiltrate mainly consists of neutrophils and eosinophils.
It is therefore possible that expression of podoplanin and
LYVE-1 on BVs is related to changed leukocyte recruitment
patterns in acute versus chronic lesions. It is known that
adhesion molecule expression patterns change during time.
In the early phase of skin inflammation, EC express high
levels of E-selectin, P-selectin, some VCAM-1, and are
negative for sialyted, fucosylated, and/or sulfated carbohy-
drate moieties. In chronic lesions, EC express some
E-selectin, robust VCAM-1 (Petzelbauer et al., 1993, 1994),
and express fucosylated and sulfated carbohydrates (Lechleit-
ner et al., 1999; Renkonen et al., 2002). We thus suggest that
podoplanin and LYVE-1 expression by BV endothelium
extents the list of molecules displayed on BECs in chronic
skin inflammation.
In conclusion, we describe a previously unknown
cytokine-induced BV phenotype in chronic skin inflamma-
tion. They express low amounts of podoplanin and LYVE-1.
This clearly distinguishes them from LVs, which constitutively
express high amounts of these molecules. Thus, podoplanin
and LYVE-1 are not only lineage markers for LEC, but have to
be considered as activation markers for BEC.
MATERIALS AND METHODS
Cells
Foreskin-derived microvascular ECs were isolated as described
(Petzelbauer et al., 1995). Briefly, foreskins were treated with dispase
(Invitrogen/GIBCO, Carlsbad, CA) for 20 minutes at 371C, followed
by mechanically scraping ECs with a cell scraper. Cells were seeded
into fibronectin-coated wells and cultured in EC growth medium
(MV/ECGS; PromoCell, Heidelberg, Germany). Fibroblasts were
removed by magnetic sorting using CD31 mAbs. BEC and LEC were
separated by sorting with an anti-podoplanin serum. Phenotypes of
BEC and LEC cultures have been described recently (Kriehuber et al.,
2001; Gro¨ger et al., 2004); BEC were PAL-E, N-cadherin, CXCR4
positive; LEC were podoplanin, LYVE-1, Prox-1 positive.
Antibodies
First step Abs were as follows: PAL-E (RDI, Flanders, NJ), anti-
podoplanin rabbit serum (Kriehuber et al., 2001; Gro¨ger et al.,
E-selectin Podoplanin LYVE-1
Blood vessels (PAL-E+/CD31+)
Lymphatic vessels (PAL-E–/CD31+)
100%
60%
20%
100%
60%
20%
w/o culture Medium 
 control
IL-3 TNF /IFN/IL-3
Figure 4. Summary of E-selectin, podoplanin, and LYVE-1 expression profiles
of BVs and LVs in organ-cultured skin. Randomly photographed, triple
stained LSM images from the papillary dermis of organ-cultured skin were
analyzed blinded to the condition (five images/sample; n¼ 7 in each
treatment condition, meanþ SD). Ab combinations were PAL-E and CD31,
together with one of the following third Abs: E-selectin, podoplanin, or
LYVE-1. Numbers of PAL-Eþ /CD31þ BVs or PAL-E/CD31þ LVs expressing
either E-selectin, podoplanin, or LYVE-1 were counted.
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2004), mouse monoclonal anti-human podoplanin (Kerjaschki et al.,
2006), anti-LYVE-1 (RDI), anti-E-selectin (R&D Systems Inc., MN),
CD45RO (Dako, Glostrup, DK), FITC-labeled anti-E-selectin (RDI),
FITC-labeled anti-ICAM-1 (R&D Systems Inc.), and FITC-labeled
anti-VCAM-1 (R&D Systems Inc.), FITC-labeled CD31 (Immunotech,
Marseille-Cedex, France), and Cy3-labeled anti-smooth muscle
alpha actin (clone1A4, Sigma). As negative controls, the respective
isotype controls were used (Sigma-Aldrich, St Louis, MO). As an
additional negative control, the anti-podoplanin serum was pre-
incubated with a recombinant Fc-podoplanin fusion protein
(Breiteneder-Geleff et al., 1999).
Second step Abs were: Alexa488-labeled anti-mouse IgG
(Invitrogen/Molecular Probes, Carlsbad, CA), tetramethyl ruodamine
isothiocyanate (TRITC) or Alexa488-labeled anti-rabbit IgG (Invitro-
gen/Molecular Probes). The following second step Abs were F(ab)2
fragments; Cy5-labeled goat anti-mouse IgG (Jackson Laboratories,
West Grove, PA), phycoerythrin-labeled goat anti-rabbit IgG (BD
Biosciences Pharmingen, NJ), Cy5-labeled goat anti-rabbit IgG
(Jackson Laboratories).
Inflamed skin samples and organ-cultured skin
Inflamed skin sections were obtained from formalin-fixed, paraffin-
embedded material from patients that underwent a diagnostic biopsy
for medical reasons; only biopsies from trunks or upper limbs were
included into this evaluation. All patients had signed an informed
consent before the diagnostic biopsy stating that material that is not
needed for the diagnostic procedures can be used for scientific
purposes under the premise that enough material remains in case
additional diagnostic procedures will become necessary thereafter.
This was approved by the Institutional Review Board of the Medical
University of Vienna and conducted according to declarations of
Helsinki Principles. The patients’ diagnosis was established by
clinical and histological means. From each biopsy, 10 sections (5 mm
each) were taken for these experiments and deparaffinized according
to standard procedures.
For organ cultures, skin derived from plastic surgery specimen
according to the protocol described above was incubated at 371C,
5% CO2 in a humidified incubator for 24 hours in EC growth
medium (MV w/o ECGS; PromoCell), without or with the addition of
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Figure 5. Cultured BEC and LEC differ in their cytokine-induced phenotype. Foreskin-derived BEC and LEC were cultured in the absence or presence of the
indicated cytokines for 24 hours. (a) Protein expression was determined by FACS using the indicated Abs (meanþ SD; three independent experiments). The
y-axis shows mean fluorescence intensity (MFI). (*) denotes significant differences in antigen expression between unstimulated and cytokine-stimulated BEC,
as well as between BEC and LEC (Po0.05). BEC’, LEC . (b) Real-time PCR for mRNA expression of the indicated lymphatic markers (one of three experiments
shown, each performed in triplicates). (c) Real-time PCR for mRNA expression of the indicated adhesion molecules (one of three experiments shown, each
performed in triplicates). The y-axis represents DDCt values ( 106). The Ct value represents the cycle number at which the fluorescence passes a fixed
threshold value. Ct values were normalized to glyceraldehyde-3-phosphate dehydrogenase and calculated relative to the water control using the formula 2
DDCt.
For (b) and (c): control, TNFa/IFNg, and ’ TNFa/IFNg/IL-3.
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the indicated cytokines, as described previously (Petzelbauer et al.,
1993). Then, samples were snap frozen, cut into 4 mm sections, and
fixed in acetone.
For immunohistochemistry, sections were incubated with the
indicated first step reagents followed by appropriate second step Abs.
Bound Abs were visualized by incubation with a streptavidin-HRP
conjugate (Dako) and 3-amino, 9 ethyl-laisazole (AEC), resulting in a
red-colored reaction product. Sections were counterstained with
hematoxylin. For immunofluorescence triple stainings, the indicated
first step Abs were either directly labeled with a fluorescent dye or
bound Abs were visualized by fluorescence-labeled second step Abs.
In all experiments, the respective isotype controls were run in parallel.
Sections were analyzed by a confocal laser scan microscope (LSM
510, Zeiss, Oberkochen, Germany). The pinhole of the LSM was set to
an airy unit of 1, resulting in a section thickness of 0.8mm.
Quantification of immunofluorescence
The following procedure was followed for evaluating paraffin
sections: for each Ab used, at least two sections from each biopsy
were stained by triple immunofluorescence technique and five
images from the papillary dermis were randomly obtained. Each
LSM image was stored as an electronic file and then analyzed by of
three independent observers blinded to the conditions. Numbers of
SMA/podoplaninhighþ , SMAþ /podoplaninlowþ , and SMAþ /
podoplanin were counted were set in relation to the total numbers
of CD31þ vessels.
For evaluation of cryostat sections, following was the procedure:
Ab combinations were PAL-E and CD31, together with one of the
following third Abs, E-selectin, podoplanin, or LYVE-1. Five
randomly selected LSM images of the papillary dermis were
analyzed blinded to the conditions. Numbers of PAL-Eþ /CD31þ
BVs or numbers of PAL-E/CD31þ LVs expressing either E-selectin,
podoplanin, or LYVE-1 were counted.
FACS
Cells were detached from culture dishes using trypsin/EDTA
(Invitrogen/GIBCO). Samples were incubated with the indicated
first step fluorescence labeled Abs. Isotype-matched control Abs
were used in parallel. Bound fluorescence was analyzed by FACScan
(Becton Dickinson, BD Sciences, San Jose, CA).
Real-time PCR
BEC and LEC were cultivated in the absence or presence of the
indicated cytokines. Then, RNA was isolated and reverse transcribed
as described (Gro¨ger et al., 2004). Real-time PCR was carried out with
a TaqMAN Universal PCR Master Mix kit (Applied Biosystems, Foster
City, CA), according to the manufacturer’s instructions. Primer kits for
glyceraldehyde-3-phosphate dehydrogenase (assay-IDs Hs9999990
m1), podoplanin (Hs00366764 m1), Prox-1 (Hs00896293 m1), LYVE-
1 (Hs00272659 m1), E-Selectin (Hs00174057 m1), and VCAM-1
(Hs00174239 m1) were purchased from Applied Biosystems. PCR was
performed on an ABI Prism 7700 Sequence Detector using the
following cycling conditions: 951C for 10 minutes followed by 40
cycles of 951C (15 seconds) and 601C (1 minute). The Ct value
represents the cycle number at which the fluorescence passes a fixed
threshold value. Ct values were normalized to glyceraldehyde-3-
phosphate dehydrogenase and calculated relative to the water control
using the formula 2DDC t .
Statistical analysis
Results are presented in a primary descriptive manner (mean7SD).
Significance among the groups was calculated by Student’s t-test and
considered significant when Po0.05.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported in part by a research grant from the Austrian Science
Foundation (FWF S9402-BII).
SUPPLEMENTARY MATERIAL
Figure S1. Examples of individual FACS curves for podoplanin surface
expression.
Figure S2. Examples of individual FACS curves for E-selectin, ICAM-1, and
VCAM-1 expression.
Figure S3. Adhesion molecule expression after 72 hours of cytokine
stimulation.
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